Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineNo recent work listed

Yuhan Yang

Matched on ORCID iD 0000-0002-4177-6396; OpenAlex author ID A5102721724. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 9

  1. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11239-w↗
  2. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Co-author DOI 10.1016/j.yexcr.2022.113402↗
  3. Correction to "Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression … Co-author DOI 10.4251/wjgo.v14.i10.2085↗
  4. M2 Macrophage-Derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2. Co-author DOI 10.1016/j.ymthe.2020.11.024↗
  5. Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT ax… Co-author DOI 10.4251/wjgo.v13.i11.1709↗
  6. Identification of a novel PAK1 inhibitor to treat pancreatic cancer. Co-author DOI 10.1016/j.apsb.2019.11.015↗
  7. Hypoxic Tumor-Derived Exosomal Long Noncoding RNA UCA1 Promotes Angiogenesis via miR-96-5p/AMOTL2 in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2020.08.021↗
  8. Tumor-Infiltrating Leukocyte Compositions and Prognostic Immune-Related Genes in Pancreatic Cancer. First author DOI 10.21203/rs.3.rs-119677/v1↗
  9. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. Co-author DOI 10.3748/wjg.v26.i19.2349↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zengya Guo · 8 shared papers, 2020–2023 · strength 1.16
  2. Zhengjun Qiu · 8 shared papers, 2020–2023 · strength 1.16
  3. Buwei Teng · 5 shared papers, 2020–2022 · strength 0.70
  4. Kun-Dong Zhang · 3 shared papers, 2020–2022 · strength 0.46
  5. Chen Huang · 3 shared papers, 2020–2023 · strength 0.39
  6. Peng Cao · 3 shared papers, 2020–2023 · strength 0.38
  7. Xiaofeng Wang · 3 shared papers, 2020–2021 · strength 0.36
  8. Haitao Gu · 2 shared papers, 2022–2023 · strength 0.35
  9. Xuan Han · 1 shared paper, 2023 · strength 0.16
  10. Weiwei Chen · 1 shared paper, 2020 · strength 0.11
  11. Gang Cen · 1 shared paper, 2020 · strength 0.11
  12. Jiaqi Wang · 1 shared paper, 2020 · strength 0.10
  13. Xueting Cai · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.